Fate’s unparalleled scientific team is backed by leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all with successful track records in building some of the world’s leading life sciences companies.
The syndicate group has a combined $7 billion under management. Ground-breaking biotechnology companies founded by the firms and their partners include Immunex, IDEC Pharmceuticals, Gilead Sciences, Genetics Institute, Illumina, Centocor, Sepracor, Alnylam Pharmaceuticals, Athena Neurosciences, Aviron, Corixa, deCode Genetics, Geron, Ikaria, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Sirna Therapeutics, Trubion Pharmaceuticals, Vical and XenoPort.
|
ARCH Venture Partners
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in information technology, life sciences, and physical sciences. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages six funds totaling over $1.4 billion and has invested in the earliest venture capital rounds for more than 110 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. The partnership is led by seven managing directors and a team of venture partners, principals, and technology specialists.
Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced venture capital investors and technology executives. The firm’s mission is to identify and invest in seed, first round, and early stage information technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies. In addition, Polaris is committed to providing growth equity and shareholder liquidity to established companies in the technology, healthcare, manufacturing, media, communications, and business services sectors. As a national venture capital firm with offices in the high-tech centers of Boston and Seattle, Porlaris is able to invest in businesses throughout the United States and around the world. The firm has over $3 billion under management and current investments in more than 90 companies.
Venrock
Venrock is a premier venture capital firm with offices in Menlo Park, New York, Cambridge, MA, and Israel, with a primary focus on technology, healthcare, and energy. Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $1.9 billion in 405 companies resulting in 124 IPOs and 114 M&A exits over the past 38 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance.
OVP Venture Partners
For over 24 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVP’s strategy of focusing on early-stage investments in defined spaces has yielded proven results; the firm’s record of 52 liquidity events – including 22 IPOs – leads the region. The OVP team has a passion for working with ground-breaking entrepreneurs and high-caliber investors, and is known for its track record and personal integrity. OVP has over $750 million in capital under management and is currently investing its seventh fund.OVP has offices in Seattle and Portland and concentrates on opportunities at the intersection of technology’s next big waves and foundational strengths native to the region. The firm’s recent activity has included deals in communications, software, security, semiconductors, digital biology, and nanotechnology.
|
